posted on 2013-04-16, 00:00authored byLeo W.
Y. Yeung, Shona J. Robinson, Jan Koschorreck, Scott A. Mabury
A total of 420 human plasma from
two cities (Halle and Münster,
Germany) collected between 1982 and 2009, were analyzed for a suite
of PFSAs (C4, C6, C8, C10) and selected PFOS precursors (MeFOSAA,
EtFOSAA, FOSAA, di-SAmPAP). Among these target analytes, only di-SAmPAP
was used in consumer products. PFSAs (C6 and C8), MeFOSAA, EtFOSAA,
and FOSAA were detected in over 95% of the samples (<0.0011–116.0
ng/mL), PFDS was detected in approximately 40% of the samples (<0.005–0.0998
ng/mL), and di-SAmPAP was detected in 17% of the samples (<0.005–0.0137
ng/mL). Significant positive correlations were found between PFOS
and PFHxS, MeFOSAA, EtFOSAA, and FOSAA. Temporal trends of decreasing
concentration were identified for PFOS, MeFOSAA, EtFOSAA, and FOSAA,
but not for PFHxS. Di-SAmPAP, a common food-contact paper surfactant
and expected PFOS precursor, was detected infrequently (25% in samples
prior to 2000) in samples before 2006. Population halving times of
PFOS, MeFOSAA, EtFOSAA, and FOSAA were estimated. The observed reduction
of these chemicals over time in human plasma is presumably related
to the phase-out of POSF-based products beginning in 2000. The detection
of di-SAmPAP in human sera is significant because this chemical is
expected to be metabolized or degraded to PFOS in humans and the environment.
Our detection of di-SAmPAP is the first confirmation of human exposure
to this commercially available product which is a plausible source
of PFOS in humans.